Drugs / 177Lu-DFC413
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07261631 | Nov 2025 → May 2029 expected | colorectal cancer, invasive ductal and lobular carcinoma, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma +2 | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-DFC413 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07261631 ↗ |